177 342

Cited 2 times in

Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017

DC Field Value Language
dc.contributor.author이병완-
dc.date.accessioned2018-07-20T11:56:25Z-
dc.date.available2018-07-20T11:56:25Z-
dc.date.issued2017-
dc.identifier.issn2233-6079-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161521-
dc.description.abstractThe Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Diabetes Association-
dc.relation.isPartOfDIABETES & METABOLISM JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleInsulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorByung-Wan Lee-
dc.contributor.googleauthorJin Hwa Kim-
dc.contributor.googleauthorSeung-Hyun Ko-
dc.contributor.googleauthorKyu-Yeon Hur-
dc.contributor.googleauthorNan-Hee Kim-
dc.contributor.googleauthorSang Youl Rhee-
dc.contributor.googleauthorHyun Jin Kim-
dc.contributor.googleauthorMin Kyong Moon-
dc.contributor.googleauthorSeok-O Park-
dc.contributor.googleauthorKyung Mook Choi-
dc.contributor.googleauthorCommittee of Clinical Practice Guideline of Korean Diabetes Association-
dc.identifier.doi10.4093/dmj.2017.41.5.367-
dc.contributor.localIdA02796-
dc.relation.journalcodeJ00720-
dc.identifier.eissn2233-6087-
dc.identifier.pmid29086534-
dc.subject.keywordClinical practice guideline-
dc.subject.keywordDiabetes mellitus, type 2-
dc.subject.keywordHypoglycemic agents-
dc.subject.keywordInsulin-
dc.subject.keywordKorea-
dc.contributor.alternativeNameLee, Byung Wan-
dc.contributor.affiliatedAuthorLee, Byung Wan-
dc.citation.volume41-
dc.citation.number5-
dc.citation.startPage367-
dc.citation.endPage373-
dc.identifier.bibliographicCitationDIABETES & METABOLISM JOURNAL, Vol.41(5) : 367-373, 2017-
dc.identifier.rimsid61426-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.